M. Koti* and D. R. Siemens.The evolving landscape of bladder tertiary lymphoid structures. (2023). Journal of Urology. DOI: 10.1097/JU.0000000000003530.


M. Koti*, T.Bivalacqua, P. C. Black, T.Cathomen, M. Galsky, J. L. Gulley, M. Ingersoll, A.M. Kamat, W. Kassouf, T. Powles, D. R. Siemens, J. Gao. Adaptive Immunity in Genitourinary Cancers. (2023). European Urology Oncology. DOI: https://doi.org/10.1016/j.euo.2023.03.002


Yolmo, S. Rahimi, S. Chenard, G. Consëil, D. Jenkins, K. Sachdeva, I. Emon, J. Hamilton, M. Xu, M. Rangachari, D. M. Berman, D. R. Siemens, M. Koti*. Carcinogen induced expansion of atypical B cells and pre-treatment tumor adjacent tertiary lymphoid structures associate with poor response to BCG in non-muscle invasive bladder cancer. (2022). bioRxiv preprint DOI: https://doi.org/10.1101/2022.12.30.522127.


Shakfa, D. Li, G. Conseil, E. Lightbody, J. Wilson-Sanchez, A. Hamade, S. Chenard, N. Jawa, B. Laight, A. Afriyie-Asante, K. Tyryshkin, M. Kobel, M. Koti*. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer. (2023). Journal of Immunotherapy for Cancer. DOI: 10.1136/jitc-2022-006170.


A. Hamade, D. Li, K. Tyrishkin, M. Xu,  G. Conseil, P. Yolmo, J. Hamilton,S. Chenard, D.R. Siemens and M. Koti*. Sex differences in the aging murine urinary bladder and influence on the tumor immune microenvironment of a carcinogen‑induced model of bladder cancer. (2022). Biology of Sex Differences. DOI: 10.1186/s13293-022-00428-0. PMID: 35505436


N. Shakfa, D. Li, S. Nersesian, J. Wilson-Sanchez, M. Koti*. The STING pathway: therapeutic vulnerabilities in ovarian cancer. (2022). British Journal of Cancer. DOI: 10.1038/s41416-022-01797-4. PMID: 35383278


Madhuri Koti* and D. Robert Siemens. Sex and gender differences in cancers of the genitourinary tract: the need to consider immune divergence. (2021). European Urology. DOI:https://doi.org/10.1016/j.eururo.2021.10.026. PMID: 34750036.


Stephen Chenard, Chelsea Jackson, Thiago Vidotto, Lina Chen, Céline Hardy, Tamara Jamaspishvilli, David Berman, D. Robert Siemens, Madhuri Koti*.  Sexual dimorphism in outcomes of non-muscle invasive bladder cancer: a role of CD163+ M2 macrophages, B cells and PD-L1 immune checkpoint. (2021). European Urology: Open Science. DOI:https://doi.org/10.1016/j.euros.2021.05.002. PMID: 34337534.


Stephen Chenard, D. Robert Siemens, Madhuri Koti*The CXCR3alt-CXCL11 axis in bladder cancer: potential for prediction of neoadjuvant chemotherapy response. (2021). Commentary/Research Highlight. Molecular and Cellular Immunology. https://www.nature.com/cmi/news-and-comment/. https://rdcu.be/ckCNn. PMID: 33990777.


Rachel Sue-A-Quan, Palak G Patel, Noor Shakfa, May-Phyo Nyi Nyi, Afrakoma Afriyie-Asante, Eun Young Kang, Martin Köbel, Madhuri Koti*. Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary. (2021). Gynecologic Oncology. DOI: 10.1016/j.ygyno.2021.05.010. PMID: 34088514.


Alvaro Morales, D. Robert Siemens and Madhuri KotiAt a time of global BCG shortage, attempts at optimizing BCG dose and schedule is no longer the answer. (2021). A commentary in, Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2020.10.009. PMID: 33218921.


Madhuri Koti*, Molly A. Ingersoll, Shilpa Gupta, Christa M. Lam, Xue Li, Ashish M. Kamat, Peter C. Black and D. Robert SiemensSex differences in bladder cancer immunobiology and outcomes: a collaborative review with implications for treatment. (2020). European Urology:Oncology. DOI: https://doi.org/10.1016/j.euo.2020.08.013. PMID: 32967818.


Madhuri Koti*, Alvaro Morales, Charles H. Graham, D. Robert Siemens. BCG vaccine and COVID-19: Implications for infection prophylaxis and cancer immunotherapy. (2020). Journal for ImmunoTherapy of Cancer. DOI:10.1136/ jitc-2020-001119. PMID: 32636240.


Sarah NersesianNoor ShakfaNichole PetersonThiago VidottoAfrakoma AfriyieAsanteElizabeth Lightbody, Madhuri Koti*.  Chemotherapy induced immunogenic cell death alters response to exogenous activation of STING pathway and PD-L1 immune checkpoint blockade in a syngeneic murine model of ovarian cancer. (2019). https://www.biorxiv.org/content/10.1101/824094v1.


Madhuri Koti*, Stephen Chenard, Sarah Nersesian, Thiago Vidotto, Alvaro Morales, D. Robert SiemensInvestigating the STING pathway to explain mechanisms for BCG failures in non-muscle invasive bladder cancer: prognostic and therapeutic implications. (2019). Bladder Cancer. DOI: 10.3233/BLC-190228.


Thiago Vidotto, Sarah Nersesian, Charles H. Graham, D. Robert Siemens, Madhuri Koti*. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes. (2019). Journal for ImmunoTherapy of Cancer. DOI: 10.1186/s40425-019-0619-8. PMID:31174611.


Vidotto, T., Saggioro, F. P., Jamaspishvili, T., Chesca, D. L.,  Picanco-Albuquerque, C. G., Reis, R. B., Graham,C. H., D. M. Berman, Siemens, D. R., Squire, J. A., Koti, M*. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. (2019). Prostate. DOI: 10.1002/pros.23808. PMID: 30999388


Natasha Vitkin, Sarah Nersesian, D. Robert Siemens, Madhuri Koti*. The tumour immune contexure of prostate cancer. (2019). Frontiers in Immunology. DOI: 10.3389/fimmu.2019.00603. PMID: 30984182


Abdi Ghaffari, Nichole Peterson, Kasra Khalaj, Natasha Vitkin, Andrew Robinson, Julie-Ann Francis, Madhuri Koti*.  STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. (2018)British Journal of Cancer. DOI 10.1038/s41416-018-0188-5. PMID: 30046165


Cole Clifford, Natasha Vitkin, Gillian Reid-Schachter, Julie-Ann Francis, Madhuri Koti*.  Multi-omics in high-grade serous ovarian cancer: biomarkers from genome to the immunome. (2018). American Journal of Reproductive Immunology. May 21:e12975. doi: 10.1111/aji.12975PMID: 29781548.


Madhuri Koti*, Amanda Shou Xu, Kevin Yi Mi Ren, Kash Visram, Runhan Ren, David Berman, D. Robert Siemens. Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer. (2017). Bladder Cancer. vol. 3, no. 4, pp. 259-267.

Runhan Ren, Kathrin Tyrishkin, Charles H. Graham, Madhuri Koti, D. Robert Siemens. Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance. (2017).Oncotarget. Aug 9;8(41):70982-71001.PMID: 29050337


Katrina K. Au, Nichole Peterson, Peter Truesdell, Gillian Reid-Schachter, Kasra Khalaj, Runhan Ren, Julie-Ann Francis, Charles H Graham, Andrew W. Craig and Madhuri Koti*.CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. (2017). Gynecologic Oncology. Jun;145(3):436-445.PMID: 28318643


Katrina Au, Cécile Le Page, Runhan Ren, Liliane Meunier, Kathrin Tryshkin, Nichole Peterson, Jennifer Kendall-Dupont, Timothy Childs, Julie-Ann Francis, Charles H Graham, Andrew B. Craig, Jeremy A. Squire, Anne-Marie Mes-Masson, and Madhuri Koti*(2016). STAT1 associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer.The Journal of Pathology: Clinical Research. Sep 19;2(4):259-270.PMID: 27917296


Runhan Ren, Madhuri Koti, Thomas Hamilton, Charles H. Graham, Jasmir G. Nayak, Jas Singh, Darrel E. Drachenberg, D. Robert Siemens. A primer on tumour immunology and prostate cancer immunotherapy. (2016). Can Urol Assoc J. 10  (1-2). PMID: 26977209


Madison Black, Ivraym Barsoum, Tiziana Cotechini, Peter Truesdell, D. Robert Siemens, Madhuri Koti, Andrew Craig, Charles Graham. Activation of the PD-1/PD-L1 immune checkpoint confers chemoresistance and promotes tumor metastasis. (2016). Oncotarget. PMID: 26859684


Katrina Au, Juliana Josahikan, Julie-Ann Francis, Jeremy A. Squire, Madhuri Koti*. Current state of biomarkers in ovarian cancer prognosis. (2015). Future Oncology. Dec 11 (23); 3187-95. PMID: 26551891


Madhuri Koti*, Alex Siu, Isabelle Clement, Mallikarjun Bidarimath, Gulisa Turashvilli, Andrew Edwards, Anne-Marie Mes Masson, Jeremy A. Squire. A distinct pre-existing inflammatory tumor microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. (2015). British Journal of Cancer. March 31; 112, 1215-1222. PMID: 26695556


Barsoum IB,Koti M,Siemens DR, Graham CH. Mechanisms of hypoxia-mediated immune escape in cancer. (2014). Cancer Research. Dec 15;74(24):7185-90.PMID: 25344227.

Madhuri Koti, Surinder S. Saini, Ashish Sachan and Azad K. Kaushik. Engineered Bovine Antibodies in the Development of Novel Therapeutics, Immunomodulators and Vaccines. (2014). Antibodies.  3, 205-214; doi:10.3390/antib3020205. http://www.mdpi.com/2073-4468/3/2/205.


Jeff W Martin, Susan Chilton-MacNeill, Madhuri Koti, Andre J van Wijnen, Jeremy A Squire, Maria Zielenska. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. (2014). PLoS One.  May 16;9(5). PMID: 24835790.


Geraci J, Dharsee M, Nuin P, Haslehurst A, Koti M, Feilotter HE, Evans K. Exploring high dimensional data with Butterfly: a novel classification algorithm based on discrete dynamical systems. (2014). Bioinformatics. Mar 1;30(5):712-8. PMID: 24149051.


Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. (2013). BMC Cancer.  Nov 16;13:549. PMID: 24237932.


Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. (2012). BMC Cancer. Mar 19;12:91. PMID: 22429801.


Weberpals JI, Koti M, Squire JA. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. (2011). Cancer Genetics.  Oct;204(10):525-35. PMID: 22137482.